Symbiotic microbe sets immune-cell levels related to colitis

January 23, 2014 by Elizabeth Cooney, Harvard Medical School
Symbiotic microbe sets immune-cell levels related to colitis
Credit: iStock

(Medical Xpress)—Humans need microbes and microbes need humans, a symbiotic dance whose steps scientists are just beginning to learn.

Of the trillions of microorganisms living in and on our bodies, the microbes that make their homes in our lungs and digestive tract are beginning to reveal themselves as closely entwined with multiple body systems. In many ways, this ecosystem, or the microbiome, and the body's immune system have the tightest grip on each other in this co-evolving choreography.

A Harvard Medical School team led by Dingding An, HMS instructor in microbiology and immunobiology, and Dennis Kasper, the William Ellery Channing Professor of Medicine and professor of microbiology and immunobiology, working collaboratively with a group led by Richard Blumberg, HMS professor of medicine at Brigham and Women's Hospital, has discovered an outsized role for one intestinal microbe. Working in mice, they have shown that a molecule produced by Bacteroides fragilis controls development of the animal's immune system from a very young age, dictating for life how it responds to an experimental model of the inflammatory bowel disease ulcerative colitis.

Their results are reported in the January 16 issue of Cell.

Unlike most bacteria, B. fragilis carries a specific type of fat molecule, the sphingolipids, in its membranes, which allows the bacteria to thrive in the host. Without them, B. fragilis lose the fight for survival in the host intestine. The resilience of B. fragilis led the scientists to ask what benefit the bacteria bring to the host.

Experiments showed that the bacteria's sphingolipids control levels of an immune cell that spurs inflammation in the host. These lipids don't act directly on the , which are called invariant natural killer T (iNKT), but they interfere with their rapid growth. These lipids likely compete with activating host lipids for space on the molecule CD1d, whose job is to present foreign material to stimulate the iNKT cells. The binding between the bacterial sphingolipids and CD1d jams the iNKT cell activation, preventing them from proliferating in great numbers.

It might seem that when defending against invaders, the more iNKT cells the better, but the reverse is true in certain situations. Too many iNKT cells can cause the runaway inflammation that leads to . Asthma, psoriasis and atherosclerosis—conditions that fall into the autoimmune disease camp—are also characterized by immune overreaction.

"The number of iNKT cells is really critical," An said. "You need to tightly control those numbers for health."

An's experiments showed that iNKT cells proliferate very early in the development of the immune system of mice. There appears to be a narrow window of a few days during which healthy levels of iNKT cells are regulated by the B. fragilis lipids.

"It's like a thermostat set at a few days of age," Kasper explained. "Once it's set, you can't move it. It's set for life."

When the scientists tried to induce colitis in older mice that had moderate numbers of iNKT cells thanks to B. fragilis lipids, they couldn't trigger the telltale inflammation. The immune system's "thermostat" protected them.

When they tried to transplant this immune advantage into mice that lacked the sphingolipid-producing microbiome by infusing the B. fragilis sphingolipid molecule during the first a few days of life, the procedure protected them from the colitis challenge in adulthood.

Two years ago, Kasper, An and their collaborator Rick Blumberg reported in Science that microbes regulated host iNKT cell levels and function through a cell recruitment mechanism. This regulation is independent of bacterial sphingolipids. It results in controlled iNKT cell numbers in both the lung and the colon, which protect the mice from asthma and colitis experimental challenges.

Kasper also discovered another molecule in B. fragilis with the power to modulate the , and published the finding in Nature several years earlier. Called polysaccharide A, or PSA, it helps to enrich in the host a kind of immune cell, regulatory T cells, priming them to release an anti-inflammatory cytokine, interleukin-10, in the presence of inflammation.

PSA seems to be a natural anti-inflammatory, Kasper said. Based on those studies in animals, it not only can prevent Crohn's disease and multiple sclerosis, but it also can be therapeutic after the onset of disease.

"We now have purified and characterized the second known example of immunomodulatory produced by symbionts," An said. "Our data indicate that treatment with these molecules and molecules like them have great potential for therapeutic applications in diseases where iNKT cell activities are destructive."

B. fragilis may be among many symbionts working with their hosts' immune systems.

"I think the microbiome is probably loaded with these sorts of molecules," Kasper said.

Explore further: How invariant natural killers keep tuberculosis in check

More information: "Sphingolipids from a Symbiotic Microbe Regulate Homeostasis of Host Intestinal Natural Killer T Cells." Dingding An, Sungwhan F. Oh, Torsten Olszak, Joana F. Neves, Fikri Y. Avci, Deniz Erturk-Hasdemir, Xi Lu, Sebastian Zeissig, Richard S. Blumberg, Dennis L. Kasper. Cell - 16 January 2014 (Vol. 156, Issue 1 and 2, pp. 123-133) DOI: 10.1016/j.cell.2013.11.042

"Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function." Torsten Olszak, Dingding An, Sebastian Zeissig, Miguel Pinilla Vera, Julia Richter, Andre Franke, Jonathan N. Glickman, Reiner Siebert, Rebecca M. Baron, Dennis L. Kasper, and Richard S. Blumberg. Science 27 April 2012: 336 (6080), 489-493.Published online 22 March 2012 [DOI: 10.1126/science.1219328]

Related Stories

How invariant natural killers keep tuberculosis in check

January 2, 2014
Mycobacterium tuberculosis is a major cause of death worldwide, and a formidable foe. Most healthy people can defend themselves against tuberculosis, but they need all parts of their immune system to work together. A study ...

Lipids produced within the thymus give immune cells the initial boost they need to fight off infection

September 12, 2012
Semi-invariant natural killer T (iNKT) cells wage war against infectious threats, attacking microbial cells and generating signals that enable other immune cells also to respond aggressively. iNKT cells initially undergo ...

Collaborative effects of multiple bacterial strains in the gut may help prevent onset of certain inflammatory diseases

September 27, 2013
At first, it may sound alarming to learn that a population of bacteria in your gut is conspiring to suppress your immune system—however, this is actually good news. By identifying the strains responsible, a research team ...

Jump-starting cheaper cancer vaccines

September 26, 2012
Dendritic cells (DCs)—workhorses of the immune system—derived from human embryonic stem cells (hESCs) may provide an economical way of generating off-the-shelf therapeutic vaccines against cancers, according to research ...

Boosting immune responses against leukaemia

November 21, 2012
(Medical Xpress)—In the first of its kind, a translational study undertaken at the Malaghan Institute of Medical Research has revealed that boosting the activity of a rare type of immune cell could be an effective way to ...

Scientists discover special class of natural fats stimulates immune cells to fight diseases

April 2, 2012
An international research team led by scientists from Singapore Immunology Network (SIgN) under the Agency of Science, Technology and Research (A*STAR) discovered that a special class of fatty molecules is essential for activating ...

Recommended for you

Improving vaccines for the elderly by blocking inflammation

January 22, 2018
By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.